Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BOXR1030 |
Synonyms | |
Therapy Description |
BOXR1030 is a glypican-3 (GPC3)-targeting CAR-T cell co-expressing glutamic-oxaloacetic transaminase 2 (GOT2) (AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2184). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BOXR1030 | BOXR 1030|BOXR-1030 | BOXR1030 is a glypican-3 (GPC3)-targeting CAR-T cell co-expressing glutamic-oxaloacetic transaminase 2 (GOT2) (AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2184). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05120271 | Phase Ib/II | BOXR1030 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) | Recruiting | USA | 0 |